LCK - New-wiki

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
CTNND1	catenin delta 1	Adherens junctions interactions VEGFR2 mediated vascular permeability InlA-mediated entry of Listeria monocytogenes into host cells
CTNND2	catenin delta 2			Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
DAPP1	dual adaptor of phosphotyrosine and 3-phosphoinositides 1	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Inositol 1,3,4,5-Tetrakisphosphate
DEF6	DEF6 guanine nucleotide exchange factor
DLG1	discs large MAGUK scaffold protein 1	Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RAF/MAP kinase cascade Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation
DOK1	docking protein 1	PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RET signaling
DOK2	docking protein 2	Tie2 Signaling RET signaling
DOK3	docking protein 3	Neutrophil degranulation
EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Choriocarcinoma Pancreatic cancer Gastric cancer Bladder cancer Endometrial Cancer Ovarian cancer Cholangiocarcinoma Breast cancer Cervical cancer
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Lethal congenital contractural syndrome (LCCS) Type I diabetes mellitus
ERBB4	erb-b2 receptor tyrosine kinase 4		Afatinib Fostamatinib Brigatinib Zanubrutinib
ESR1	estrogen receptor 1	Nuclear signaling by ERBB4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors RUNX1 regulates estrogen receptor mediated transcription ESR-mediated signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Extra-nuclear estrogen signaling Estrogen-dependent gene expression	Diethylstilbestrol Chlorotrianisene Conjugated estrogens Desogestrel Levonorgestrel Progesterone Lindane Raloxifene Toremifene Medroxyprogesterone acetate Testosterone Mitotane Estrone Tamoxifen Hexachlorophene Estradiol Ethynodiol diacetate Dobutamine Clomifene Dienestrol Fulvestrant Norgestimate Ethinylestradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Oxybenzone Allylestrenol Zinc Genistein Prasterone Benzophenone Equilin Compound 19 Resveratrol Compound 18 Phthalic Acid Pyrazole Stanolone Naringenin Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Quercetin Afimoxifene 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estrone sulfate Quinestrol Phenolphthalein Permethrin Ospemifene AP1081 Custirsen NP-50301 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Elacestrant Bazedoxifene Methyltestosterone beta-Naphthoflavone 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Hexestrol dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate Erteberel N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol Tibolone Eugenol Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, B Polyestradiol phosphate Norethynodrel Octocrylene Homosalate Enzacamene Zeranol Ractopamine Gestrinone Propyl Gallate 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Zinc acetate Zinc chloride Zinc sulfate, unspecified form Estriol tripropionate Fluoroestradiol F-18
ESR2	estrogen receptor 2	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling	Diethylstilbestrol Conjugated estrogens Progesterone Raloxifene Estrone Tamoxifen Estradiol Trilostane Estramustine Oxybenzone Genistein Prasterone Benzophenone Phthalic Acid Pyrazole Para-Mercury-Benzenesulfonic Acid Naringenin ICI-164384 5-Alpha-Androstane-3-Beta,17beta-Diol 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol Quercetin Afimoxifene Estriol Estrone sulfate MF101 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Bazedoxifene Prinaberel ERB-196 [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 17alpha-Estriol (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one Erteberel (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL Eugenol Octocrylene Enzacamene Equol 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Estriol tripropionate Fluoroestradiol F-18
EZR	ezrin	Netrin-1 signaling Recycling pathway of L1 Recycling pathway of L1
FAM166B	family with sequence similarity 166 member B
FAM174A	family with sequence similarity 174 member A
FAS	Fas cell surface death receptor	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TP53 Regulates Transcription of Death Receptors and Ligands Dimerization of procaspase-8 FasL/ CD95L signaling		Hodgkin lymphoma Esophageal cancer Chronic lymphocytic leukemia (CLL) Adult T-cell leukemia
FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FCGR3A	Fc fragment of IgG receptor IIIa	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Cetuximab Etanercept Human immunoglobulin G Gemtuzumab ozogamicin Alemtuzumab Alefacept Palivizumab Daclizumab Bevacizumab Catumaxomab Sarilumab Benralizumab	NK cell defects, including the following disease: CD16 deficiency Systemic lupus erythematosus

Search Results for: LCK